New Two-Pronged attack tested against aggressive lung cancer

NCT ID NCT04699838

Summary

This study is testing whether a new two-part treatment can better control an aggressive form of lung cancer and keep it from getting worse. Previously untreated patients will first receive standard chemotherapy plus an immunotherapy drug, then continue with a maintenance therapy combining two other drugs. The main goal is to see how long patients live without their cancer progressing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Illinois Medical Center

    RECRUITING

    Chicago, Illinois, 60612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Iowa Hospitals and Clinics

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact Email: •••••@•••••

    Contact

  • University of Maryland

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.